# Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

> **NCT05319015** · PHASE2 · RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Neoadjuvant Lenvatinib
- **DRUG:** Neoadjuvant Pembrolizumab
- **PROCEDURE:** Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection
- **DRUG:** Adjuvant Pembrolizumab

## Key facts

- **NCT ID:** NCT05319015
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-06
- **Primary completion:** 2026-07
- **Final completion:** 2026-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05319015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05319015, "Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05319015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*